SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil on Influenza Vaccine Immunogenicity and Stability
Award last edited on: 12/13/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$223,002
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Philip O Livingston

Company Information

Adjuvance Technologies Inc

116 West 22nd Street Suite 1
New York, NY 10010
Location: Single
Congr. District: 10
County: New York

Phase I

Contract Number: 272201700066C-0-0-1
Start Date: 8/1/2017    Completed: 7/31/2018
Phase I year
2017
Phase I Amount
$223,002
The Contractor will develop TiterQuil a semi synthetic saponin adjuvant analog of QS for the purpose of improving the immunogenicity of commercially available flu vaccines Fluzone Sanofi Pasteur Fluvirin Seqirus and Flublok Protein Sciences

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----